Galderma Readies Its First Therapeutic Biologic For Two US Launches In 2024

Phase III Data Also Show New Toxin Works Up To Six Months

Galderma said its IL-31 receptor alpha inhibitor nemolizumab succeeded in two Phase III atopic dermatitis trials, advancing the firm’s long-term goal of moving past topical dermatology drugs.

Wooden blocks with launching rocket graphic arranged in pyramid shape — Galderma is building up to its nemolizumab launch in the US next year • Source: Shutterstock

Galderma S.A.’s ongoing makeover continues with the skin care specialist revealing positive topline Phase III results in atopic dermatitis for nemolizumab. The first-in-class IL-31 receptor alpha inhibitor is poised to be the company’s first therapeutic biologic, advancing a long-term plan to shift its prescription dermatology medicines portfolio from topical treatments to systemic therapies.

Zug, Switzerland-based Galderma said on 13 March, as part of its fiscal year 2022 financial results, that it plans to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

06 Jun 2025

• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

02 Jun 2025

• By Kevin Grogan

But the French major is still keen on early-stage M&A.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

28 May 2025

• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Leo Roars To A Profit In Q1 As Adbry Grows In US

15 May 2025

• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Metsera’s Amylin Analog Stars In Obesity Phase I

09 Jun 2025

• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.